Lisa M. Gennarini
Experienced in Infantile Neutropenia
Experienced in Infantile Neutropenia

Overview

Lisa Gennarini, MD, has been an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology and Blood & Marrow Cell Transplantation at Children's Hospital at Montefiore (CHAM) since 2014. Her clinical focus is on treatment of children with leukemia and lymphoma as well as various vascular anomalies. She is also the CHAM Principal Investigator for Children?s Oncology Group trials, and also leads the CHAM Vascular Malformations Program. Dr. Gennarini graduated from Siena College in 2004, earning her Bachelor of Science in Biology. In 2008, she received her Doctor of Medicine at State University of New York, Upstate Medical University in Syracuse. She began a residency in Pediatrics at Jefferson Medical College/A.I. duPont Hospital for Children, followed by a fellowship in Pediatric Hematology/Oncology at Children?s Hospital at Montefiore. Dr. Gennarini's work on pediatrics, topics ranging from sickle cell disease to implementing communications skills training courses in pediatric hematology/oncology, has been published in various journals and books, and presented nationally. Dr. Gennarini is board certified by the American Board of Pediatrics in Pediatric Hematology/Oncology and General Pediatrics.

Dr. Gennarini is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Intersex, Bone Marrow Aspiration, and Adenoidectomy.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 46 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Infantile Neutropenia.

Graduate Institution
SUNY Syracuse
Residency
A I Dupont Hosptl For Children
Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in NY
Fellowships
Montefiore Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Archcare
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
The Wellness Plan Medical Centers
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

The Children's Hospital at Montefiore
3415 Bainbridge Avenue, Bronx, NY 10467
Other Locations
Montefiore at 1250 Waters Place
1250 Waters Place, Bronx, NY 10461

Additional Areas of Focus

Dr. Gennarini has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


46 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 40 Less Clinical Trials
Similar Doctors
Advanced in Infantile Neutropenia
Hematology Oncology | Oncology | Hematology
Advanced in Infantile Neutropenia
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

428 E 72nd St, Ofc 300, 
New York, NY 
 (8.8 miles away)
Languages Spoken:
English
Offers Telehealth

Cara Rosenbaum is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Rosenbaum is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Daniel A. Weiser
Experienced in Infantile Neutropenia
Hematology | Oncology
Experienced in Infantile Neutropenia
Hematology | Oncology

The Children's Hospital At Montefiore

3415 Bainbridge Avenue, 
Bronx, NY 
 (0.1 miles away)
Languages Spoken:
English

Daniel A. Weiser, MD, is a board-certified pediatric hematologist/oncologist with clinical expertise in neuroblastoma and tumors of the adrenal glands, kidneys, liver, and gonads. He serves as Director of the Abdominal Solid Tumor Program and Co-Director of the Childhood Cancer Predisposition (CCP) Clinic at the Children’s Hospital at Montefiore Einstein. Dr. Weiser leads a highly specialized, multidisciplinary team dedicated to providing comprehensive and individualized care for children with a broad spectrum of solid tumors. Dr. Weiser is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Adult Soft Tissue Sarcoma, and Osteosarcoma.

Adit L. Tal
Experienced in Infantile Neutropenia
Hematology | Oncology
Experienced in Infantile Neutropenia
Hematology | Oncology

The Children's Hospital At Montefiore

3415 Bainbridge Avenue, 
Bronx, NY 
 (0.1 miles away)
Languages Spoken:
English

Adit Tal, MD, is an Attending Physician at Children’s Hospital at Montefiore Einstein (CHAM) and an Assistant Professor of Pediatric Hematology, Oncology, Marrow and Blood Cell Transplantation at our Albert Einstein College of Medicine. Since joining the Montefiore team, Dr. Tal’s clinical focus has been the treatment of pediatric leukemia and lymphoma, and the supportive care of children with cancer. Dr. Tal is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Gliomatosis Cerebri, Infantile Neutropenia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gennarini's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile